Determining modes of binding and activation of complex G-protein coupled receptor targets

Grant number: 1043750 | Funding period: 2013 - 2015



The peptide hormones relaxin is currently in a Phase III trial for the treatment of heart failure. However the peptide is not a good drug as it can't be taken orally and is very expensive to produce. We will study the interaction of relaxin and the related peptide INSL3 with their cell surface receptors and the mechanisms by which the receptors function. The knowledge gained will aid in the design of smaller, more potent and orally active forms of relaxin which will be able to be used as drugs for the treatment of heart failure.

Related publications (16)

University of Melbourne Researchers